Analytical and Clinical Performance of a Novel Immunoassay-Based Test System to Predict Diabetic Kidney Disease
The Journal of Applied Laboratory Medicine · 2025
DOI: 10.1093/jalm/jfaf097 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von James K C Lui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics International, QEII Medical Centre, Perth, WA, Australia. Hauptthemen laut MEDLINE: Biomarkers, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Apolipoproteins A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia.
Abstract (Originalsprache)
Background
Diabetes-related chronic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD), requiring costly dialysis or kidney transplantation. Existing standard- of-care tests for DKD have several limitations, and an alternative is Promarker®D, a validated plasma biomarker test system that predicts DKD in adults with diabetes up to 4 years before symptoms develop.
Methods
To enable high-throughput application of PromarkerD, a novel CaptSureTM immunoassay version of the test was developed targeting plasma biomarkers Apolipoprotein A4 (ApoA4) and CD5 antigen-like (CD5L). The analytical performance of the assay was assessed, and clinical samples from 2 independent clinical cohorts (>1700 adults with type 2 diabetes [T2D]) were used for the development and external validation of the DKD predictive test.
Results
The PromarkerD test system combined ApoA4 and CD5L concentrations with clinical factors age and estimated glomerular filtration rate (eGFR) to calculate risk scores (0% to 100%) and classify study participants as either at low, moderate, or high risk for future kidney decline. PromarkerD demonstrated reliable analytical performance and provided a high discriminative capability in adults with T2D (receiver operating characteristic area under the curve [ROC-AUC]: 0.78 to 0.88) to predict 4-year kidney decline, defined as incident DKD (eGFR <60 mL/min/1.73 m2) or eGFR decline ≥40%, with sensitivity of 75.8% to 85.1% at the moderate-risk cutoff and specificity of >92% at the high-risk cutoff across the two cohorts.
Conclusion
The next-generation PromarkerD test system offers a convenient yet highly effective tool for DKD risk assessment. By introducing PromarkerD to standard diabetes care, preventative treatment strategies may be implemented early before permanent kidney function loss occurs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Proteomics International, QEII Medical Centre, Perth, WA, Australia.
- Medical School, Fremantle Hospital, University of Western Australia, Fremantle, WA, Australia.
ORCID-Profile: Kirsten E Peters, Scott D Bringans
Förderung
- National Health and Medical Research Council of Australia
Zitieren
APA
Lui, J. K. C., Peters, K. E., Fernandez, G., Joubert, I. A., Lumbantobing, T. S. C., Davis, T. M. E., Lipscombe, R. J., & Bringans, S. D. (2025). Analytical and Clinical Performance of a Novel Immunoassay-Based Test System to Predict Diabetic Kidney Disease. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf097
Vancouver
Lui JKC, Peters KE, Fernandez G, Joubert IA, Lumbantobing TSC, Davis TME, et al. Analytical and Clinical Performance of a Novel Immunoassay-Based Test System to Predict Diabetic Kidney Disease. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfaf097
BibTeX
@article{Lui2025,
author = {Lui, James K C and Peters, Kirsten E and Fernandez, Gareth and Joubert, Isabella A and Lumbantobing, Tasha S C and Davis, Timothy M E and Lipscombe, Richard J and Bringans, Scott D},
title = {Analytical and Clinical Performance of a Novel Immunoassay-Based Test System to Predict Diabetic Kidney Disease},
journal = {The Journal of Applied Laboratory Medicine},
year = {2025},
doi = {10.1093/jalm/jfaf097}
}
EUVIMED